Use of trastuzumab for breast cancer: The role of age

Walter Mazzucco, Marta Rossi, Rosanna Cusimano, Matteo Franchi, Martina Bonifazi, Alessandro Mistretta, Francesco Vitale, Walter Ricciardi, Eva Negri, Stefania Boccia, Carlo La Vecchia

Research output: Contribution to journalArticlepeer-review


Indication for the use of trastuzumab was given in Italy in 2000 for the treatment of HER-2 metastatic breast cancer and in 2006 for early stage breast cancer. Information on trastuzumab use and on its possible variation with age in Italy is however limited. Using health care administrative databases, we evaluated the prevalence of the use of trastuzumab, and the probability for administration since the first hospitalization for breast cancer in various age groups, in two series of Italian women diagnosed with breast cancer in the Lombardy region (2004-2009) and in the Palermo district. The ratio between trastuzumb users and patients with a hospitalization for breast cancer increased from 2.9% in 2004 up to 17.2% in 2009 in Lombardy. Patients aged

Original languageEnglish
Pages (from-to)5957-5962
Number of pages6
JournalCurrent Pharmaceutical Design
Issue number38
Publication statusPublished - Jan 1 2014


  • Breast cancer treatment
  • Early breast cancer
  • Elderly
  • Metastatic breast cancer
  • Trastuzumab

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Medicine(all)


Dive into the research topics of 'Use of trastuzumab for breast cancer: The role of age'. Together they form a unique fingerprint.

Cite this